BARICITINIB IN THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN CHINA: 24-WEEK RESULTS OF POSTMARKETING SAFETY STUDY

被引：0
|
作者：
Wu, C. Y. [1 ]
Wang, Q. [1 ]
Shi, J. [2 ]
Zhang, X. [3 ]
Du, R. [4 ]
Gu, J. [5 ]
Liu, Q. H. [6 ]
Yu, J. [1 ,7 ]
Xu, J. W. [1 ,7 ]
Zhang, Y. J. [1 ,7 ]
Zhu, H. [1 ]
Li, M.
Zeng, X.
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp PUMCH, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China
[2] Yiyang Cent Hosp, Dept Rheumatol & Clin Immunol, Yiyang, Peoples R China
[3] Zibo Cent Hosp, Dept Rheumatol & Clin Immunol, Zibo, Peoples R China
[4] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Tongji Med Coll, Dept Rheumatol & Clin Immunol, Wuhan, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol & Clin Immunol, Guangzhou, Peoples R China
[6] Hubei Univ Med, Sinopharm Dongfeng Gen Hosp, Dept Rheumatol & Clin Immunol, Shiyan, Peoples R China
[7] Eli Lilly & Co, LCDDMAC, Shanghai, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Real-world evidence; Safety; Rheumatoid arthritis;
D O I：
10.1136/annrheumdis-2023-eular.2148
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0455 AB0
引用
收藏
页码：1418 / 1418
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study
    Guidelli, G. M.
    Viapiana, O.
    Luciano, N.
    De Santis, M.
    Boffini, N.
    Quartuccio, L.
    Birra, D.
    Conticini, E.
    Chimenti, M. S.
    Bazzani, C.
    Bruschi, E.
    Riva, M.
    Canziani, L. M.
    Bianchi, G.
    Pozzi, M. R.
    Limonta, M.
    Gorla, R.
    Perricone, R.
    Frediani, B.
    Moscato, P.
    De Vita, S.
    Dagna, L.
    Rossini, M.
    Selmi, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (04) : 868 - 873
  • [42] Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy
    Tasso, M.
    Bertolini, N.
    Mostacciuolo, E.
    Passavanti, S.
    Luppino, J. M. E.
    Del Puente, A.
    Peluso, R.
    Santelli, F.
    Scarpa, R.
    Costa, L.
    Caso, F.
    REUMATISMO, 2022, 74 (03) : 131 - 136
  • [43] Ustekinumab for severe treatment-resistant psoriasis: a 24-week pilot study in Hong Kong Chinese
    Loo, S. K. F.
    Lau, K. H.
    Ho, K. M.
    HONG KONG JOURNAL OF DERMATOLOGY & VENEREOLOGY, 2011, 19 (02): : 59 - 64
  • [44] Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
    Strand, Vibeke
    Burmester, Gerd R.
    Ogale, Sarika
    Devenport, Jenny
    John, Ani
    Emery, Paul
    RHEUMATOLOGY, 2012, 51 (10) : 1860 - 1869
  • [45] Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
    Tian, Lei
    Xiong, Xiaomo
    Guo, Qiang
    Chen, Yixi
    Wang, Luying
    Dong, Peng
    Ma, Aixia
    PHARMACOECONOMICS, 2020, 38 (12) : 1345 - 1358
  • [46] Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis
    Goldenberg, MM
    CLINICAL THERAPEUTICS, 1999, 21 (01) : 75 - 87
  • [47] Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
    Harigai, Masayoshi
    Takeuchi, Tsutomu
    Smolen, Josef S.
    Winthrop, Kevin L.
    Nishikawa, Atsushi
    Rooney, Terence P.
    Saifan, Chadi G.
    Issa, Maher
    Isaka, Yoshitaka
    Akashi, Naotsugu
    Ishii, Taeko
    Tanaka, Yoshiya
    MODERN RHEUMATOLOGY, 2020, 30 (01) : 36 - 43
  • [48] Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience
    Fargnoli, M. C.
    Esposito, M.
    Dapavo, P.
    Parodi, A.
    Rossi, M.
    Tiberio, R.
    Dastoli, S.
    Offidani, A. M.
    Argenziano, G.
    Gisondi, P.
    Lo Schiavo, A.
    Loconsole, F.
    Pella, P.
    Bardazzi, F.
    Cusano, F.
    Gattoni, M.
    Nacca, M.
    Cannavo, S. P.
    Pellegrini, C.
    Costanzo, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (03) : 693 - 700
  • [49] Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
    Philip Conaghan
    Stanley Cohen
    Gerd Burmester
    Eduardo Mysler
    Peter Nash
    Yoshiya Tanaka
    William Rigby
    Jayeshkumar Patel
    Tim Shaw
    Keith A. Betts
    Pankaj Patel
    Jianzhong Liu
    Rochelle Sun
    Roy Fleischmann
    Rheumatology and Therapy, 2022, 9 : 191 - 206
  • [50] Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
    Tanaka, Yoshiya
    Emoto, Kahaku
    Cai, Zhihong
    Aoki, Takehiro
    Schlichting, Douglas
    Rooney, Terence
    Macias, William
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (03) : 504 - 511
12345